论文部分内容阅读
目的:评价聚乙二醇干扰素α-2a(polyethylene glycol interferon alpha-2a,PEG-IFNα-2a)联合利巴韦林(ribavirin,RBV)治疗转氨酶正常的慢性丙型肝炎(chronic hepatitis C,CHC)的临床疗效和安全性.方法:对转氨酶正常(18 mo至少有3次以上的化验结果证实转氨酶均在正常范围者)和升高的慢性丙型肝炎患者按照应答指导治疗策略给予PEG-IFNα-2a(180 g/wk)联合RBV(≤65kg 800 mg/d,>65 kg-<75 kg 1000 mg/d,≥75kg 1200 mg/d)治疗,并随访24 wk.分别于治疗4、12 wk及治疗结束后24 wk评价疗效,并观察药物不良反应.结果:共有161例患者完成治疗,其中73例实验组患者和88例对照组患者入组的基本情况相似.实验组和对照组的快速病毒学应答(78.1%vs 75.0%,P>0.05)、完全早期病毒学应答(93.2%vs 92.0%,P>0.05)和持续病毒学应答(92.7%vs 91.9%,P>0.05)相近,差异无统计学意义.结论:PEG-IFNα-2a联合RBV治疗转氨酶正常的CHC是安全有效的.
Objective: To evaluate the efficacy of polyethylene glycol interferon alpha-2a (PEG-IFNα-2a) combined with ribavirin (RBV) in the treatment of normal hepatic transaminase-associated chronic hepatitis C ) Clinical efficacy and safety.METHODS: PEG-IFNα was given to patients with elevated aminotransferases (at least 3 more tests at 18 months confirmed transaminases in the normal range) and patients with elevated chronic hepatitis C according to a response-directed treatment strategy -2a (180 g / wk) combined with RBV (≤65 kg 800 mg / d,> 65 kg- <75 kg 1000 mg / d, ≥75 kg 1200 mg / d) and were followed up for 24 weeks wk and 24 wk after the end of treatment to evaluate the curative effect and to observe adverse drug reactions.Results: A total of 161 patients completed the treatment, of which 73 patients in the experimental group and 88 patients in the control group entered the basic situation is similar to the experimental group and control group The results of rapid virological response (78.1% vs 75.0%, P> 0.05), complete early virological response (93.2% vs 92.0%, P> 0.05) and sustained virologic response (92.7% vs 91.9%, P> The difference was not statistically significant.Conclusion: PEG-IFNα-2a combined with RBV in the treatment of normal transaminase of CHC is safe and effective.